These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 12214460

  • 1. [Latest information in the diagnoses of ovarian carcinoma].
    Isonishi S.
    Gan To Kagaku Ryoho; 2002 Aug; 29(8):1351-7. PubMed ID: 12214460
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T, Glimelius B, Nygren P, SBU-group. Swedish Council of Technology Assessment in Health Care.
    Acta Oncol; 2001 Aug; 40(2-3):340-60. PubMed ID: 11441940
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Gynecologic malignancies.
    Schilder RJ, Scher RM, Young RC.
    Cancer Chemother Biol Response Modif; 1993 Aug; 14():530-56. PubMed ID: 8312118
    [Abstract] [Full Text] [Related]

  • 9. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.
    Ozols RF.
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):1-6. PubMed ID: 8643963
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas].
    Pete I, Szánthó A, Mayer A, Thurzó L, Pulay T.
    Orv Hetil; 2003 May 11; 144(19):919-24. PubMed ID: 12809068
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, Aydin Y, Topuz E.
    Gynecol Oncol; 2008 Jan 11; 108(1):136-40. PubMed ID: 17936342
    [Abstract] [Full Text] [Related]

  • 15. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF.
    Semin Oncol; 2000 Jun 11; 27(3 Suppl 7):3-7. PubMed ID: 10952119
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Paclitaxel/carboplatin in first line treatment of advanced ovarian carcinoma].
    Meerpohl HG.
    Praxis (Bern 1994); 1999 Mar 18; 88(12):513-8. PubMed ID: 10235026
    [Abstract] [Full Text] [Related]

  • 19. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S, EORTC-ACTION collaborators. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm.
    J Natl Cancer Inst; 2003 Jan 15; 95(2):113-25. PubMed ID: 12529344
    [Abstract] [Full Text] [Related]

  • 20. Medical treatment of epithelial ovarian cancer.
    González-Martín AJ.
    Expert Rev Anticancer Ther; 2004 Dec 15; 4(6):1125-43. PubMed ID: 15606338
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.